HOWL logo

HOWL
Werewolf Therapeutics Inc

1,035
Mkt Cap
$33.05M
Volume
370,313.00
52W High
$2.38
52W Low
$0.5301
PE Ratio
-0.51
HOWL Fundamentals
Price
$0.7381
Prev Close
$0.68
Open
$0.7173
50D MA
$0.8008
Beta
1.72
Avg. Volume
376,340.37
EPS (Annual)
-$1.33
P/B
1.33
Rev/Employee
$0.00
$10.28
Loading...
Loading...
News
all
press releases
Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $69,650.76 in Stock
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 95,412 shares of the company's stock in a transaction that occurred on Tuesday, April 28th. The stock was sold at an average price of $0.73, for a total value of $69,650.76. Following the completion of the sale...
MarketBeat·8h ago
News Placeholder
More News
News Placeholder
Werewolf Therapeutics Stock Rises Over 5% After Hours On Workforce Reduction, Including Executives
The company said that the decision to layoff 64% of its workforce was approved by its board of directions on Feb. 9.
Stocktwits·3mo ago
News Placeholder
Luke Evnin Sells 38,782 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 38,782 shares of the company's stock in a transaction on Friday, January 16th. The shares were sold at an average...
MarketBeat·3mo ago
News Placeholder
Luke Evnin Sells 30,616 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 30,616 shares of the company's stock in a transaction dated Wednesday, January 14th. The stock was sold at an...
MarketBeat·3mo ago
News Placeholder
Luke Evnin Sells 58,980 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 58,980 shares of the stock in a transaction dated Monday, January 12th. The stock was sold at an average price of...
MarketBeat·4mo ago
News Placeholder
Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $11,761.92 in Stock
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 18,378 shares of the stock in a transaction on Monday, January 5th. The shares were sold at an average price of...
MarketBeat·4mo ago
News Placeholder
Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 18,568 Shares
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 18,568 shares of the business's stock in a transaction on Friday, January 2nd. The shares were sold at an average...
MarketBeat·4mo ago
News Placeholder
Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $22,448.16 in Stock
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 35,632 shares of the company's stock in a transaction dated Friday, December 26th. The stock was sold at an...
MarketBeat·4mo ago
News Placeholder
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know
Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·5mo ago
News Placeholder
Luke Evnin Sells 37,104 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 37,104 shares of Werewolf Therapeutics stock in a transaction on Wednesday, December 10th. The stock was sold at...
MarketBeat·5mo ago
<
1
2
...
>

Latest HOWL News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.